If You Invested in Integrated Biopharma Inc (INBP)

Integrated BioPharma, Inc. (INBP) is a manufacturing company in the pharmaceutical preparation manufacturing industry that focuses primarily on vitamins, nutritional supplements and herbal products. According to multiple company press releases, Integrated BioPharma is engaged in the manufacturing, distributing, marketing and sales of these products, positioning it within the broader nutraceutical and supplement segment of the manufacturing sector.

The company’s common stock trades under the symbol INBP, and press releases describe it as operating through activities that include contract manufacturing. In several quarterly and annual results announcements, Integrated BioPharma refers to a Contract Manufacturing Segment and notes that revenue from its two largest customers in this segment represents a substantial portion of total revenue. These disclosures indicate that contract manufacturing for third parties is a central part of its operations.

Business focus and activities

In the "About Integrated BioPharma, Inc." sections of its financial results releases, the company consistently states that it is engaged primarily in the business of manufacturing, distributing, marketing and sales of vitamins, nutritional supplements and herbal products. This description highlights its role in producing and supplying nutraceutical products rather than focusing on proprietary pharmaceutical drugs.

The company’s results commentary frequently references its core business and efforts to expand its customer base. Management statements in earnings releases discuss revenue concentration in the Contract Manufacturing Segment and note that revenue from the two largest customers has represented a high percentage of total revenue in recent fiscal years and interim periods. These comments underscore both the importance of contract manufacturing and the company’s stated goal of diversifying its customer base.

Customer concentration and segments

Across multiple reporting periods, Integrated BioPharma discloses that its two largest customers in the Contract Manufacturing Segment account for a significant majority of total revenue. For example, company press releases for periods ended June 30, December 31, March 31 and September 30 in various years provide percentages showing that these two customers together contributed a large share of revenue. In one fiscal year discussion, the company also notes that its Contract Manufacturing Segment contributed the vast majority of total revenue, with additional contribution from another nutraceutical business segment described as warehousing and distribution.

Management commentary in these releases links the company’s strategy to both supporting its existing core businesses and pursuing new prospects in contract manufacturing and warehousing and distribution, with the stated objective of diversifying the customer base over time.

Regulatory and corporate governance context

Integrated BioPharma is incorporated in Delaware, as indicated in its SEC filings, including Form 8-K and its definitive proxy statement on Schedule 14A. The company’s proxy materials describe a Board of Directors divided into classes serving staggered three-year terms and outline typical annual meeting matters such as election of directors, advisory votes on executive compensation and its frequency, and ratification of the independent auditor.

The company files current reports on Form 8-K to announce financial results for quarters and fiscal years, furnishing earnings press releases as exhibits. It also files a definitive proxy statement (DEF 14A) for its annual meeting of stockholders, which provides information on proposals to be voted on, voting procedures and record date details. These filings show that Integrated BioPharma follows standard U.S. public company governance and disclosure practices.

Stockholder and meeting information

According to the company’s proxy statement and related Form 8-K, Integrated BioPharma holds an annual meeting of stockholders where holders of its common stock vote on director elections, advisory compensation matters and auditor ratification. The proxy materials specify that each share of common stock is entitled to one vote on matters presented at the meeting and describe how stockholders of record and beneficial owners can vote by mail, telephone, internet or in person.

Form 8-K disclosures regarding the annual meeting provide final voting results for each proposal, including director elections, advisory votes on executive compensation and the frequency of such votes, and ratification of the independent auditor for a specified fiscal year. These filings confirm that the company maintains an active stockholder voting process and reports outcomes through the SEC’s EDGAR system.

Financial reporting and results communication

Integrated BioPharma regularly issues press releases detailing its financial results for quarters and fiscal years, and these releases are referenced in corresponding Form 8-K filings under Item 2.02 (Results of Operations and Financial Condition). The releases include summaries of revenue, cost of sales, gross profit, selling and administrative expenses, operating income or loss, other income or expense, income tax expense or benefit, and net income or loss, along with basic and diluted net income (loss) per share and weighted average shares outstanding.

In the narrative portions of these releases, the company’s Co-Chief Executive Officers comment on revenue trends, operating performance and revenue concentration in the Contract Manufacturing Segment. They also refer to focusing on core businesses, expanding the customer base and, in some periods, growth in warehousing and distribution activities within the nutraceutical business.

Trading and registration status

Several press releases identify Integrated BioPharma’s stock as trading on the OTCQX market under the symbol INBP. In recent Form 8-K filings, the section listing securities registered under Section 12(b) of the Exchange Act states that the company has no securities registered on a national securities exchange, with "None" shown for both the title of each class and the exchange. This indicates that while the company’s common stock trades, it is not listed on a national securities exchange under Section 12(b) as of the dates of those filings.

The company’s SEC filings also reference its Commission File Number and employer identification number, confirming its status as a registrant under the Securities Exchange Act of 1934. The filings include standard checkboxes regarding solicitation material and pre-commencement communications, which are not selected in the provided documents.

Use of SEC and investor materials

In its proxy statement, Integrated BioPharma notes that its proxy statement and annual report on Form 10-K for a given fiscal year are available through a specified proxy materials website. The proxy explains how stockholders can access these materials and describes the matters to be considered at the annual meeting. The company’s financial press releases also direct interested parties to its investor relations site for further information.

For investors researching INBP stock, these disclosures together present a picture of a nutraceutical-focused manufacturer that emphasizes contract manufacturing relationships, vitamins, nutritional supplements and herbal products, and that communicates results and governance matters through regular press releases, SEC filings and annual meeting materials.